Number: CTSU S1007 Principal Investigator: Naughton, Michael
Title: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) OF 25 or Less
Phase: III Disease Site: Breast, Female
Participating Site(s):
Main Campus
Map and Directions
South County
Map and Directions
St. Peters
Map and Directions
West County
Map and Directions
Contact: 800-600-3606 or

Currently many women with breast cancer are treated with endocrine therapy. Many women also receive chemotherapy. No one really knows which patients with lower Recurrence Scores need to get chemotherapy. Some women may be getting chemotherapy who do not need it. These women may be exposed to side effects of their treatment that are not a necessary risk in relation to the benefit they receive.

The purpose of this study is to find out if the Oncotype DX® Recurrence Score can help decide whether patients should receive chemotherapy or not. This study is being done in patients with lower Recurrence Scores (25 or less).
More Information: Link
Internal Protocol Documents (requires Siteman administrative database password)